Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Pseudomonas aeruginosa carriage on ICU-acquired pneumonia: a European multicentre prospective cohort study.
Recanatini C, van Werkhoven CH, van der Schalk TE, Paling F, Hazard D, Timbermont L, Torrens G, DiGiandomenico A, Esser MT, Wolkewitz M, Sifakis F, Goossens H, Bonten M, Oliver A, Malhotra-Kumar S, Kluytmans J; ASPIRE-ICU Study Team. Recanatini C, et al. Among authors: esser mt. Clin Microbiol Infect. 2024 Nov 10:S1198-743X(24)00533-0. doi: 10.1016/j.cmi.2024.11.007. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 39532190 Free article.
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
Levin MJ, Ustianowski A, De Wit S, Beavon R, Thissen J, Seegobin S, Dey K, Near KA, Streicher K, Kiazand A, Esser MT. Levin MJ, et al. Among authors: esser mt. Infect Dis Ther. 2024 Jun;13(6):1253-1268. doi: 10.1007/s40121-024-00970-x. Epub 2024 May 4. Infect Dis Ther. 2024. PMID: 38703336 Free PMC article.
In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infection.
Tkaczyk C, Newton M, Patnaik MM, Thom G, Strain M, Gamson A, Daramola O, Murthy A, Douthwaite J, Stepanov O, Boger E, Yang H, Esser MT, Lidwell A, DiGiandomenico A, Santos L, Sellman BR. Tkaczyk C, et al. Among authors: esser mt. Mol Ther. 2024 Aug 7;32(8):2505-2518. doi: 10.1016/j.ymthe.2024.05.036. Epub 2024 May 31. Mol Ther. 2024. PMID: 38822525 Free PMC article.
Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.
Wilkins D, Yuan Y, Chang Y, Aksyuk AA, Núñez BS, Wählby-Hamrén U, Zhang T, Abram ME, Leach A, Villafana T, Esser MT. Wilkins D, et al. Among authors: esser mt. Nat Med. 2024 Jun;30(6):1785. doi: 10.1038/s41591-024-03006-6. Nat Med. 2024. PMID: 38649782 Free PMC article. No abstract available.
In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates.
Patel A, Rosenke K, Parzych EM, Feldmann F, Bharti S, Griffin AJ, Schouest B, Lewis M, Choi J, Chokkalingam N, Machado V, Smith BJ, Frase D, Ali AR, Lovaglio J, Nguyen B, Hanley PW, Walker SN, Gary EN, Kulkarni A, Generotti A, Francica JR, Rosenthal K, Kulp DW, Esser MT, Smith TRF, Shaia C, Weiner DB, Feldmann H. Patel A, et al. Among authors: esser mt. Emerg Microbes Infect. 2024 Dec;13(1):2294860. doi: 10.1080/22221751.2023.2294860. Epub 2024 Feb 28. Emerg Microbes Infect. 2024. PMID: 38165394 Free PMC article.
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.
Clegg LE, Stepanov O, Schmidt H, Tang W, Zhang H, Webber C, Cohen TS, Esser MT, Någård M. Clegg LE, et al. Among authors: esser mt. Antimicrob Agents Chemother. 2024 May 2;68(5):e0158723. doi: 10.1128/aac.01587-23. Epub 2024 Mar 27. Antimicrob Agents Chemother. 2024. PMID: 38534112 Free PMC article.
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.
Sankhala RS, Dussupt V, Chen WH, Bai H, Martinez EJ, Jensen JL, Rees PA, Hajduczki A, Chang WC, Choe M, Yan L, Sterling SL, Swafford I, Kuklis C, Soman S, King J, Corbitt C, Zemil M, Peterson CE, Mendez-Rivera L, Townsley SM, Donofrio GC, Lal KG, Tran U, Green EC, Smith C, de Val N, Laing ED, Broder CC, Currier JR, Gromowski GD, Wieczorek L, Rolland M, Paquin-Proulx D, van Dyk D, Britton Z, Rajan S, Loo YM, McTamney PM, Esser MT, Polonis VR, Michael NL, Krebs SJ, Modjarrad K, Joyce MG. Sankhala RS, et al. Among authors: esser mt. Structure. 2024 Feb 1;32(2):131-147.e7. doi: 10.1016/j.str.2023.11.015. Epub 2023 Dec 28. Structure. 2024. PMID: 38157856 Free article.
AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults.
Cai Y, Diallo S, Rosenthal K, Ren K, Flores DJ, Dippel A, Oganesyan V, van Dyk N, Chen X, Cantu E, Choudhary R, Sulikowski M, Adissu H, Chawla B, Kar S, Liu C, Dijokaite-Guraliuc A, Mongkolsapaya J, Rajan S, Loo YM, Beavon R, Webber C, Chang LJ, Thomas S, Clegg L, Zhang H, Screaton GR, Philbin N, Harre M, Selim A, Martinez-Alier N, Uriel A, Cohen TS, Perez JL, Esser MT, Blair W, Francica JR. Cai Y, et al. Among authors: esser mt. Sci Transl Med. 2024 Jun 26;16(753):eado2817. doi: 10.1126/scitranslmed.ado2817. Epub 2024 Jun 26. Sci Transl Med. 2024. PMID: 38924429
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.
Hobbs FDR, Montgomery H, Padilla F, Simón-Campos JA, Arbetter D, Seegobin S, Kiazand A, Streicher K, Martinez-Alier N, Cohen TS, Esser MT. Hobbs FDR, et al. Among authors: esser mt. Infect Dis Ther. 2024 Mar;13(3):521-533. doi: 10.1007/s40121-024-00931-4. Epub 2024 Feb 25. Infect Dis Ther. 2024. PMID: 38403865 Free PMC article.
107 results